The global Contrast Media/Contrast Agents market was valued at USD 4.25 Billion in 2016 and is expected to register a CAGR of 3.8% in the forecast period. The market is driven by factors such as the rise in the number of testing centers coupled with rising in the number of government approvals for contrast agents. Increasing cases of cancer and a rise in R&D activities add to the market growth in the forecast period. However, side effects and adverse reactions on health by use of Contrast Media/Contrast Agents are expected to restrict the market growth during the forecast period.
Contrast agents are a crucial part of radiology and massive improvements have made them efficient, safer, and fast. On the other hand, associated risks led by Contrast Media/Contrast Agents remain prevalent and emit adverse reactions in various ways. Hence, the use of Contrast Media/Contrast Agents is subject to safe use acknowledging the potential side effects. Using contrast agents in a way such that it maximizes the patient’s safety is a great deal of concern. Therefore, the use of contrast agents must be determined on a particular basis depending on the clinical condition of the patient.
Clinically the intravascular iodinated contrast agents are built upon tri-iodinated benzene rings with existence in three primary forms. The forms include high-osmolar contrast media are the oldest agents and relatively expensive with a limited utility. Monomers that dissolve in water but never dissociate and are referred to as low-osmolar contrast media (LOCM) and a class of agents comprising a molecular with two benzene rings are referred to as iso-osmolar contrast media (IOCM).
The Contrast Media market is segmented based on agent type, modality, application, and region. Type category for the market includes barium-based, gadolinium-based, microbubble, and iodinated. The modality category is segmented into CT, MRI, ultrasound, and X-Ray.
Geographical segmentation for Contrast Agents market spans North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa. The North American market is expected to dominate the market in the forecast period due to government initiatives taken by key players coupled with the presence of well-built healthcare infrastructure and the availability of advanced technologies. In addition, the constant demand for diagnostic procedures contributes to the market growth in the forecast period.
Rising investments coupled with active R&D activities are likely to propel APAC’s market growth shortly along with rising cancer incidences, growth in investment in emerging economies adds to the market growth in the APAC market sector. The key players in the Contrast Media market include Bayer AG, GE Healthcare, Guerbet, Lantheus Medical Imaging, and Bracco Diagnostics.
Market Segment:
Contrast Media Type Outlook (Revenue, USD Billion, 2016 - 2025)
• Iodinated contrast media
• Barium-based contrast media
• Gadolinium-based contrast media
• Microbubble contrast media
Contrast Agents Modality Outlook (Revenue, USD Billion, 2016 - 2025)
• X-ray/CT contrast agents
• MRI contrast agents
• Ultrasound contrast agents
Contrast Media Application Outlook (Revenue, USD Billion, 2016 - 2025)
• Cardiovascular disorders
• Neurological disorders
• Gastrointestinal disorders
• Cancer
• Nephrological disorders
• Musculoskeletal disorders
• Others
Contrast Media Regional Outlook (Revenue, USD Billion, 2016 - 2025)
• North America
• U.S.
• Canada
• Europe
• U.K.
• France
• Asia
• Japan
• India
• Row
Research Support Specialist, USA